Table 2.

Association of sCTLA-4 serum levels with best overall response (BOR) in IPI-treated MM patients

sCTLA-4 levels	Total	irCR + irPR		irSD		irPD		irSD vs irCR + irPR			irPD vs irCR + irPR
		N	%	N	%	N	%	OR	95%CL	p value	OR	95%CL	p value
≤ 200 pg/ml	57	7	36.8	7	43.8	43	55.1	1.00	(Ref.)	0.169	1.00	(Ref.)	0.020
> 200 pg/ml	56	12	63.2	9	56.3	35	44.9	0.23	0.03–1.88		0.11	0.02–0.71
Whole sample	113	19	100.0	16	100.0	78	100.0	–	–	–	–	–	–

Association of sCTLA-4 serum levels with BOR was estimated through a multinomial logistic regression modelling using the value 200 pg/ml as cutoff point for serum sCTLA-4 levels. Detection of sCTLA-4 levels was performed by ELISA. All samples were tested in duplicate with deviation between duplicates lower than 10% for any reported value

IPI ipilimumab, irCR immune-related complete response, irPR immune-related partial response, irSD immune-related stable disease, irPD immune-related progressive disease, OR odds ratio adjusted for age at 1st IPI cycle, gender, time from diagnosis, LDH levels, dNLR pre-IPI immunotherapy, brain, liver and cutaneous metastases and participating center, 95%CL 95% confidence, p value significance level of the likelihood ratio test, Ref. reference category